We described here that NAMPT is expressed in CCA, and FK866, a new small-molecule NAMPT inhibitor, may be a potential targeted medication for the treatment of patients with CCA as it was found in the current investigation to block NAMPT-mediated NAD synthesis, affecting cell metabolism and proliferation preferentially in tumor cells compared to normal cholangiocytes. This evidence concerns the gene NAMPT and cholangiocarcinoma.